CARE consortium dispatches to quicken drug discovery and improvement for COVID-19 Kumar Jeetendra | August 19, 2020 Using a grant approximately $77.7 million, CARE is funded by cash donations by the European Union (EU) and money and in-kind contributions from Australian European Federation of Pharmaceutical Industries and Associations (EFPIA) businesses and three IMI-Associated Partners. CARE is a five-year project bringing together 37 partners from Belgium, China, Denmark, France, Germany, the Netherlands, Poland, …
Novel medication could improve future and quality for patients with difficult to-treat malignant growths Kumar Jeetendra | September 9, 2020 The Sheffield researchers founded the spin-out Modulus Oncology with a group of experienced biotech entrepreneurs to fast-track the drug into clinical testing over two decades. The researchers founded the spin-out firm Modulus Oncology, along with a team of seasoned biotech entrepreneurs, to fast-track the drug into clinical testing over two years. The Sheffield team made …
Translational exploration preparing program causes understudies to more readily comprehend patients’ issues Kumar Jeetendra | September 27, 2020 Translational research aims to speed research breakthroughs into the practice. And yet, training for basic scientists and clinicians too often remains siloed, resulting in divergent cultures and a lack of chance for cross-disciplinary collaboration. The South Carolina Clinical & Translational Research (SCTR) Institute’s TL1 application, a translational research training program for doctoral students in the …
Second-generation double antibody shields from SARS-CoV-2 and its tried variations Kumar Jeetendra | January 25, 2021 Additionally, it prevents the virus from mutating to resist the treatment . Antibody-based immunotherapy was already proven to work against COVID-19 but faces two chief obstacles: it requires to work against the circulating viral variants; it has to avoid formation of new variants, that can rapidly ensue using a mechanism similar to that leading to …
New COVID-19 testing innovation is a less expensive, quicker choice to tube-based RT-PCR tests Kumar Jeetendra | May 18, 2021 Throughout the COVID-19 pandemic, supply chain shortages of reagents and test kits have restricted the rapid expansion of clinical testing required to contain the virus. Its accuracy was 100 percent predictive in clinical trials, researchers explain in The Journal of Molecular Diagnostics, published by Elsevier. Sensitivity is critical for early detection of COVID-19 infection where …
Novel antibody candidate shows powerful binding to different SARS-CoV-2 variant mutations Kumar Jeetendra | September 25, 2021 Twist Bioscience Corporation today reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent binding to diverse SARS-CoV-2 variant mutations, including strains with the E484K, N501Y, D614G, Y453F and K417N mutations in pseudovirus assays, indicating this therapeutic antibody may be effective in treating many strains of COVID-19. The Coronavirus Immunotherapy Consortium (CoVIC) is an academic-industry-non-profit …
